This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Avelumab (genetical recombination)

July 30, 2025

Therapeutic category

Other antitumor agents

Non-proprietary name

Avelumab (genetical recombination)

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

| Current | Revision |
|--|--|
| 8. IMPORTANT PRECAUTIONS | 8. IMPORTANT PRECAUTIONS |
| Hepatic failure, hepatic impairment, and hepatitis may occur. | Hepatic failure, hepatic impairment, hepatitis, and sclerosing |
| Patients should be carefully monitored through periodic liver function | cholangitis may occur. Patients should be carefully monitored |
| tests. | through periodic liver function tests. |
| | |
| 11. ADVERSE REACTIONS | 11. ADVERSE REACTIONS |
| 11.1 Clinically Significant Adverse Reactions | 11.1 Clinically Significant Adverse Reactions |
| Hepatic failure, hepatic impairment, hepatitis | Hepatic failure, hepatic impairment, hepatitis, sclerosing cholangitis |
| Hepatic failure, hepatic impairment accompanied by increased levels | Hepatic failure, hepatic impairment accompanied by increased levels |
| of AST, ALT, γ-GTP, bilirubin, etc., and hepatitis may occur. | of AST, ALT, γ-GTP, bilirubin, etc., hepatitis, and sclerosing |
| | cholangitis may occur. |